Zapping tumors: electric fields tested against pancreatic cancer
NCT ID NCT07319910
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This program gives adults with locally advanced pancreatic cancer access to a device that delivers gentle electric fields to the abdomen, combined with standard chemotherapy. The goal is to see if this approach is safe and feasible while the device awaits FDA approval. Participants must be able to use the device themselves or with help from a caregiver.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TTFields (electric fields) plus gemcitabine and nab-paclitaxel chemotherapy
- What this could lead to
- If it works, this could offer a new treatment option for people with locally advanced pancreatic cancer, potentially slowing tumor growth.
- What could go wrong
- This is an early access program, not a full trial, so effectiveness is not yet proven. The device requires daily wear and may cause skin irritation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Four-Drug cocktail aims to shrink pancreatic tumors before surgery
- Immune cells armed with antibody take on pancreatic cancer
- New drug AB801 aims to boost chemo and immunotherapy in tough cancers
- New PET tracer could light up pancreatic tumors
- New drug combo aims to tackle pancreatic cancer in patients with inherited gene mutations
- Blasting pancreatic tumors with extra radiation may open door to surgery